Late-Life Delusional Depression: Acute and Long-Term Treatment

Treatment studies of delusional major depression demonstrate a poor response to standard antidepressant medications. Longitudinal studies demonstrate high relapse rates, even in patients receiving postdischarge antidepressants. The poor medical and psychiatric outcomes for late-life delusional depression and the increased risk for adverse medication reactions in this population underscore the importance of developing effective postrecovery treatments.Studies of mixed-age adults demonstrate the effectiveness of acute treatment with either electroconvulsive therapy or combination pharmacotherapy with high doses of neuroleptics and antidepressants. In considering these results in relation to the treatment of late-life delusional depression, attention must be given to the particular vulnerabilities to medication side effects of elderly patients.The potential effectiveness of continuation treatment with combined antidepressant-neuroleptic therapy is discussed. Clinical and methodologic issues related to studying the effectiveness of combination treatment in elderly patients are emphasized.

Download Full-text

1608: Long-Term Treatment with High Doses of Sildenafil Does Not Up-Regulate the Levels of Phosphodiesterase 5 (Pde5) in the Rat Penis

The Journal of Urology ◽

10.1016/s0022-5347(18)38816-5 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 424-424 ◽

Cited By ~ 7

Author(s):

Monica G. Ferrini ◽

Eliane G. Valente ◽

Jacob Rajfer ◽

Nestor F. Gonzalez-Cadavid

Keyword(s):

Term Treatment ◽

Long Term Treatment ◽

High Doses ◽

Phosphodiesterase 5

Download Full-text

565 The tissue effects of long-term treatment with ACE inhibitor and metoprolol in elderly patients with congestive heart failure (CHF) and preserved systolic function

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(06)80362-0 ◽

2006 ◽

Vol 5 (1) ◽

pp. 127-127

Author(s):

O SOYA ◽

O KURYATA

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Elderly Patients ◽

Ace Inhibitor ◽

Systolic Function ◽

Term Treatment ◽

Tissue Effects ◽

Long Term Treatment

Download Full-text

Long-Term Treatment with ‘Duovent’ in Elderly Patients Affected by Chronic Obstructive Lung Disease

Respiration ◽

10.1159/000195137 ◽

1986 ◽

Vol 50 (2) ◽

pp. 245-248

Author(s):

L. Cecere ◽

G. Funaro ◽

G. De Cataldis ◽

P. Carnicelli ◽

R. Pinto

Keyword(s):

Elderly Patients ◽

Lung Disease ◽

Obstructive Lung Disease ◽

Chronic Obstructive Lung Disease ◽

Term Treatment ◽

Chronic Obstructive ◽

Long Term Treatment

Download Full-text

Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications

Therapeutic Advances in Drug Safety ◽

10.1177/2042098617690485 ◽

2017 ◽

Vol 8 (6) ◽

pp. 173-182 ◽

Cited By ~ 39

Author(s):

Andrea Fanelli ◽

Daniela Ghisi ◽

Pierangelo Lora Aprile ◽

Francesco Lapi

Keyword(s):

Term Treatment ◽

Cyclooxygenase 2 ◽

Thrombotic Risk ◽

Long Term Treatment ◽

Pressure Development ◽

Inflammatory Drugs ◽

Anti Inflammatory ◽

High Doses ◽

The Right ◽

Meta Analyses

Observational studies and meta-analyses have shown that the administration of nonsteroidal anti-inflammatory drugs (NSAIDs), especially when prescribed at high doses for long periods of time, can potentially increase the risk of cardiovascular diseases. The increased thrombotic risk related to the use of NSAIDs is mainly due to their cyclooxygenase 2 selectivity. The dosage use, the formulation selected and the duration of the therapy are other factors that can significantly impact on the cardiovascular risk. In order to minimize the risk, prescription of the right drug based on the patient’s features and the different safety profiles of several NSAIDs that are available on the market is key for their appropriate administration. Despite the baseline cardiovascular and gastrointestinal risk of each patient, monitoring of patients is suggested for increases in blood pressure, development of edema, deterioration of renal function, or gastrointestinal bleeding during long-term treatment with NSAIDs.

Download Full-text

Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence

Bioscience Reports ◽

10.1042/bsr20180845 ◽

2019 ◽

Vol 39 (1) ◽

Cited By ~ 7

Author(s):

Saif Khan ◽

Raju K. Mandal ◽

Abdulbaset Mohamed Elasbali ◽

Sajad A. Dar ◽

Arshad Jawed ◽

...

Keyword(s):

Gene Polymorphisms ◽

Meta Analysis ◽

Term Treatment ◽

Wild Type ◽

Severe Problem ◽

Trial Sequence ◽

Increased Risk ◽

Long Term Treatment ◽

Nat2 Gene

Abstract Hepatotoxicity is a severe problem generally faced by tuberculosis (TB) patients. It is a well-known adverse reaction due to anti-TB drugs in TB patients undergoing long-term treatment. The studies published previously have explored the connection of N-acetyltransferase 2 (NAT2) gene polymorphisms with isoniazid-induced hepatotoxicity, but the results obtained were inconsistent and inconclusive. A comprehensive trial sequence meta-analysis was conducted employing 12 studies comprising 3613 controls and 933 confirmed TB cases using the databases namely, EMBASE, PubMed (Medline) and Google Scholar till December 2017. A significant association was observed with individuals carrying variant allele at position 481C>T (T vs. C: P = 0.001; OR = 1.278, 95% CI = 1.1100–1.484), at position 590G>A (A vs. G: P = 0.002; OR = 1.421, 95% CI = 1.137–1.776) and at position 857G>A (A vs. G: P = 0.0022; OR = 1.411, 95% CI = 1.052–1.894) to higher risk of hepatotoxicity vis-à-vis wild-type allele. Likewise, the other genetic models of NAT2 gene polymorphisms have also shown increased risk of hepatotoxicity. No evidence of publication bias was observed. These results suggest that genetic variants of NAT2 gene have significant role in isoniazid induced hepatotoxicity. Thus, NAT2 genotyping has the potential to improve the understanding of the drug–enzyme metabolic capacity and help in early predisposition of isoniazid-induced hepatotoxicity.

Download Full-text

Combination of oxybutynin transdermal patch and heparinoid cream for long-term treatment of overactive bladder in elderly patients

Dermatology Aspects ◽

10.7243/2053-5309-6-1 ◽

2018 ◽

Vol 6 (1) ◽

pp. 1

Author(s):

Yoshihito Murakami ◽

Hiroshi Nagae ◽

Naomi Maehori ◽

Hidehisa Sekijima ◽

Kazuya Ooi

Keyword(s):

Overactive Bladder ◽

Elderly Patients ◽

Term Treatment ◽

Transdermal Patch ◽

Long Term Treatment

Download Full-text

Maintenance pharmacotherapy of unipolar depression

Psychiatric Bulletin ◽

10.1192/pb.23.6.370 ◽

1999 ◽

Vol 23 (6) ◽

pp. 370-373 ◽

Cited By ~ 3

Author(s):

Som Forshall ◽

David J. Nutt

Keyword(s):

Prophylactic Treatment ◽

Unipolar Depression ◽

Term Treatment ◽

Current Evidence ◽

Full Remission ◽

Long Term Treatment ◽

Continuation Treatment ◽

Term Maintenance ◽

Review Current

Aims and methodsThe purpose of this paper is to review current evidence and opinion with regard to the long-term treatment of unipolar depression. The method employed was a Psychlit search using the search items long-term, maintenance, treatment and depression.ResultsThe search yielded 91 articles.Clinical implicationsUnipolar depression is frequently recurrent and sometimes a chronic illness. The paper identifies those at greatest risk of recurrence. It goes on to examine strategies to prevent relapse and for prophylactic treatment. It concludes that continuation treatment should be sustained at full dose for 4–6 months after full remission of symptoms. Where depression is highly recurrent the acute phase dose should be maintained in the long-term.

Download Full-text

Medical Consequences of Long-term Treatment of Acromegaly

European Endocrinology ◽

10.17925/ee.2010.06.00.68 ◽

2010 ◽

Vol 06 ◽

pp. 68

Author(s):

Rosario Pivonello ◽

Renata S Auriemma ◽

Mariano Galdiero ◽

Ludovica FS Grasso ◽

Annamaria Colao ◽

...

Keyword(s):

Signs And Symptoms ◽

Premature Death ◽

Term Treatment ◽

Tumour Mass ◽

Risk Of Death ◽

Increased Risk ◽

Long Term Treatment ◽

A Minor ◽

The Impact

This article discusses the impact of long-term treatment of acromegaly on cardiovascular, metabolic, respiratory and articular complications as well as on malignancies. The main goals of treatment of acromegaly include normalisation of biochemical markers of disease activity, improvement in signs and symptoms of the disease, removal or reduction of tumour mass and preservation of pituitary function, together with prevention of complications. Cardiovascular and respiratory complications are the main causes of morbidity and mortality, whereas neoplasms are a minor cause of increased risk of death. Other associated diseases are arthropathy, carpal tunnel syndrome and reproductive disorders. The prolonged elevation of growth hormone (GH) and insulin-like growth factor (IGF)-I levels results in premature death, whereas strong biochemical control improves wellbeing and restores life expectancy to normal.

Download Full-text